Sivelestat sodium

PreclinicalSmall molecule

TThe First Hospital of Jilin University

Sivelestat sodium is one of 55 small molecule programs targeting Sepsis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

SepsisActive, not recruiting

COVID-19Active, not recruiting

Acute Ischemic StrokeRecruiting

Aortic DissectionActive, not recruiting

SepsisPreclinical

Active, not recruiting

COVID-19Preclinical

Active, not recruiting

Acute Ischemic StrokePreclinical

Recruiting

Aortic DissectionPreclinical

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Bnt162b2

BioNTech

Preclinical

29 2

Aldactone

Pfizer

Preclinical

1 3

Nitrostat

VViatris Specialty LLC

Preclinical

1 4

SARS-COV-2 VACCINE

Moderna

Preclinical

2 5

Glucocorticoid

AbbVie

Preclinical

1 6

Orap

Teva

Preclinical

1 7

HB-Admscs

HHope Biosciences Research Foundation

Preclinical

4 8

Biological Data

UUniversity Hospital, Bordeaux

Preclinical

3 9

Blood Collection

AAssistance Publique - Hôpitaux de Paris

Preclinical

1 10

Blood Taken

HHospices Civils de Lyon

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Post-ApprovalNot yet recruiting

Aortic Dissection

NCT07156656

Q2 2029

PreclinicalRecruiting

Acute Ischemic Stroke

NCT07552610

Clinical

Trials by Indication[1]

Sepsis2 trials

Protective Effect of Sivelestat Sodium on ARDS in Patients With Sepsis

Unknown status·SSoutheast University, China·Phase 3·NCT04973670·238 enrolled

Neutrophil Elastase Inhibitor in Treatment of ARDS Patients With Mechanical Ventilation Caused by Sepsis

Unknown status·TThe First Hospital of Jilin University·N/A·NCT05672472·100 enrolled

Treatment2 trials

Effect of Early Treatment With Sivelestat Sodium in ARDS Patients

Unknown status·NNanfang Hospital, Southern Medical University··NCT05020210·560 enrolled

Treatment of ARDS With Sivelestat Sodium

Recruiting·SSichuan Provincial People's Hospital·Phase 4·NCT04909697·324 enrolled

Aortic dissection2 trials

Sivelestat Treatment for Postoperative Organ Protection in Type A Aortic Dissection

Not yet recruiting·SShanghai Zhongshan Hospital·Phase 4·NCT07156656·236 enrolled

Improvement of Pulmonary Insufficiency After Aortic Dissection With Sivelestat Sodium

Unknown status·FFirst Affiliated Hospital Xi'an Jiaotong University·N/A·NCT05343338·168 enrolled

COVID-191 trial

Clinical Effects of Sivelestat Sodium on Improving ARDS in Patients With COVID-19

Completed·TThe First Hospital of Jilin University··NCT06218862·387 enrolled

Efficacy and Safety1 trial

Efficacy and Safety of Sivelestat Sodium and Dexamethasone in the Treatment of ARDS

Recruiting·PPeking Union Medical College Hospital·N/A·NCT06387823·300 enrolled

1 more indication

Acute Ischemic Stroke1 trial

Efficacy and Safety of Sivelestat Sodium as an Adjunct to Endovascular Thrombectomy in Acute Anterior Circulation Large-Vessel Occlusion: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study

Recruiting·XXuanwu Hospital, Beijing·Preclinical·NCT07552610·868 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for Sivelestat sodium. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Sivelestat sodium compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Sivelestat sodium. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — The First Hospital of Jilin University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: TThe First Hospital of Jilin University

Sivelestat sodium

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Q2 2029

Trials by Indication[1]

Sepsis2 trials

Treatment2 trials

Aortic dissection2 trials

COVID-191 trial

Efficacy and Safety1 trial

Acute Ischemic Stroke1 trial

References

Drug Info

Quick Facts

Related News